Haas JS - Search Results

1

Medicare formulary coverage for top-selling biologics.

Liang SY, Haas JS, Phillips KA. Liang SY, et al. Among authors: haas js. Nat Biotechnol. 2009 Dec;27(12):1082-4. doi: 10.1038/nbt1209-1082. Nat Biotechnol. 2009. PMID: 20010576 Free PMC article. No abstract available.

2

Angiotensin receptor blockers on the formularies of Medicare drug plans.

Gellad WF, Huskamp HA, Phillips KA, Haas JS. Gellad WF, et al. Among authors: haas js. J Gen Intern Med. 2007 Aug;22(8):1172-5. doi: 10.1007/s11606-007-0235-z. Epub 2007 May 15. J Gen Intern Med. 2007. PMID: 17503103 Free PMC article.

3

Does patient cost sharing matter? Its impact on recommended versus controversial cancer screening services.

Liang SY, Phillips KA, Tye S, Haas JS, Sakowski J. Liang SY, et al. Among authors: haas js. Am J Manag Care. 2004 Feb;10(2 Pt 1):99-107. Am J Manag Care. 2004. PMID: 15011810 Free article.

4

Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.

Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Haas JS, et al. Ann Intern Med. 2005 Jun 7;142(11):891-7. doi: 10.7326/0003-4819-142-11-200506070-00006. Ann Intern Med. 2005. PMID: 15941695 Free article.

5

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.

Phillips KA, Marshall DA, Haas JS, Elkin EB, Liang SY, Hassett MJ, Ferrusi I, Brock JE, Van Bebber SL. Phillips KA, et al. Among authors: haas js. Cancer. 2009 Nov 15;115(22):5166-74. doi: 10.1002/cncr.24574. Cancer. 2009. PMID: 19753618 Free PMC article.

6

How the new medicare drug benefit could affect vulnerable populations.

Gellad WF, Huskamp HA, Phillips KA, Haas JS. Gellad WF, et al. Among authors: haas js. Health Aff (Millwood). 2006 Jan-Feb;25(1):248-55. doi: 10.1377/hlthaff.25.1.248. Health Aff (Millwood). 2006. PMID: 16403761 Free PMC article.

7

Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer.

Liang SY, Phillips KA, Wang G, Keohane C, Armstrong J, Morris WM, Haas JS. Liang SY, et al. Among authors: haas js. Med Care. 2011 Jun;49(6):e1-8. doi: 10.1097/MLR.0b013e318207e87e. Med Care. 2011. PMID: 21422962 Free PMC article.

8

Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care.

Haas JS, Liang SY, Hassett MJ, Shiboski S, Elkin EB, Phillips KA. Haas JS, et al. Breast Cancer Res Treat. 2011 Nov;130(2):619-26. doi: 10.1007/s10549-011-1628-6. Epub 2011 Jun 17. Breast Cancer Res Treat. 2011. PMID: 21681446 Free PMC article.

9

Genomic testing and therapies for breast cancer in clinical practice.

Haas JS, Phillips KA, Liang SY, Hassett MJ, Keohane C, Elkin EB, Armstrong J, Toscano M. Haas JS, et al. J Oncol Pract. 2011 May;7(3 Suppl):e1s-7s. doi: 10.1200/JOP.2011.000299. J Oncol Pract. 2011. PMID: 21886507 Free PMC article.

10

Prescription drug dispensing limits and patterns.

Phillips KA, Liang SY, Haas JS, Stebbins M, Alldredge BK. Phillips KA, et al. Among authors: haas js. Manag Care Interface. 2005 Jul;18(7):41-6. Manag Care Interface. 2005. PMID: 16060485

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

337 results

Search Page

Filters